Here is the design of a clinical trial:

Official Title: A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis

Included conditions:
- Staphylococcus Aureus Bacteremia

Study Armgroups:
- {'label': 'Ceftobiprole medocaril', 'type': 'EXPERIMENTAL', 'description': 'Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)', 'interventionNames': ['Drug: Ceftobiprole medocaril']}
- {'label': 'Daptomycin', 'type': 'ACTIVE_COMPARATOR', 'description': 'Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam', 'interventionNames': ['Drug: Daptomycin']}

Interventions:
- {'type': 'DRUG', 'name': 'Ceftobiprole medocaril', 'description': 'Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion', 'armGroupLabels': ['Ceftobiprole medocaril']}
- {'type': 'DRUG', 'name': 'Daptomycin', 'description': 'Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam', 'armGroupLabels': ['Daptomycin']}

Primary Outcomes:
- {'measure': 'Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit', 'description': 'Comparison of overall success rates in the mITT population\n\nOverall success at PTE for the mITT population was defined as all of the following criteria being met (Responder):\n\n1. Patient alive at Day 70 (± 5 days) post-randomization.\n2. No new metastatic foci or complications of the SAB infection.\n3. Resolution or improvement of SAB-related clinical signs and symptoms.\n4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)', 'timeFrame': 'PTE visit on Day 70 (± 5 days) post-randomization'}

Please estimate the sample size based on the assumption: 
A one-sided alpha level of 0.025; power of >80%; approximately 90% of patients in the ITT population will have confirmed SAB and will be included in the mITT population.
Planned sample size
        The sample size has been estimated based on: a point estimate for overall success of 40% in each treatment group in the mITT population; a one-sided alpha level of 0.025; power of >80%; and a noninferiority margin of 15% for the between-group difference in the primary end point. The assumption of an overall success rate of 40% in each treatment group is based on the success rates in the Phase III study of daptomycin compared with standard-of-care treatment in patients with SAB including IE [8]. With these assumptions, enrollment of 350Â patients (175 per group) is required for the mITT population. Based on the previously mentioned daptomycin Phase III study [8], it is assumed that approximately 90% of patients in the ITT population will have confirmed SAB and will be included in the mITT population, and therefore a total of 390Â patients (195 per group) will need to be randomized and receive treatment. This sample size will provide â¥80% power to reject the null hypothesis (H0) against the alternative hypothesis (HA) at the one-sided alpha level of 0.025 as follows, using a two-group large-sample normal approximation test of proportions:H0:Pdaptomycin-PceftobiproleÂ â¥0.15Â versusÂ HA:Pdaptomycin-Pceftobiprole<0.15